Most studies on TP53 and survival among breast cancer patients have classified TP53 status using either DNA sequencing or immunohistochemistry (IHC) to detect nuclear overexpression of TP53 protein as a surrogate marker of mutation status. This evidence concerns the gene TP53 and breast carcinoma.